IP10对HIV/AIDS患者免疫激活作用的研究进展  

Advances of IP10 on immune activation in HIV/AIDS patients

作　　者：林铃[1] 曹玮[1] 李太生[1] LIN Ling;CAO Wei;LI Tai-sheng(Department of Infectious Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院感染内科,100730

出　　处：《传染病信息》2018年第6期505-510,共6页Infectious Disease Information

基　　金："十三五"国家科技重大专项(2017ZX10202101);中国医学科学院医学与健康科技创新工程项目(2017-I2M-1-014)

摘　　要：HIV感染者即使接受了规律有效的抗病毒治疗,其体内仍然存在慢性长期的免疫激活,这已被证明是引起许多HIV相关非AIDS并发症的重要原因。其中固有免疫激活系统产生的趋化因子干扰素-γ诱导蛋白10(interferon gammainduced protein 10, IP10)近年来在HIV研究领域受到更多的关注。IP10是一种由干扰素刺激基因产生的趋化蛋白,在HIV感染者疾病进展,与HIV感染者体内的适应性免疫系统相互作用,影响病毒储存库,引起非AIDS相关并发症方面起到重要作用。降低IP10水平或可为HIV感染者的治疗提供新的思路,为AIDS的功能性治愈奠定基础。Even if HIV-infected patients receive regular and effective antiviral therapy,there is still chronic long-term immune activation in their body,which has been proved to be an important cause of many HIV associated non-AIDS complications.Interferon gamma-induced protein10(IP10),which is produced by the innate immune activation system,has attracted more attention in the field of HIV research in recent years.IP10is a chemotactic protein produced by interferon-stimulated genes and plays an important role in HIV-infected disease progression,interaction with adaptive immune systems in HIV-infected individuals,affecting viral reservoirs and causing HIV associated non-AIDS complications.Reducing the level of IP10may provide new ideas for the treatment of HIV-infected patients and lay the foundation for functional cure of AIDS.

关 键 词：干扰素-γ诱导蛋白10 免疫激活 抗反转录病毒治疗 HIV相关非AIDS并发症 

分 类 号：R512.91[医药卫生—内科学]